Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

Clinical Pharmacology in Drug Development

Volumn 2, Issue 4, 2013, Pages 336-341

  Koch, Kevin M ^a   Im, Young Hyuck ^b   Kim, Sung Bae ^c   Urruticoechea Ribate, Ander ^d   Stephenson, Joe ^e   Botbyl, Jeffrey ^f   Cartee, Leanne ^g   Holshouser, Jane ^h   Ridgway, Derry ^g  

^a GLAXOSMITHKLINE   (United States)

^b Samsung Medical Center   (South Korea)

^c Asan Medical Center   (South Korea)

^d Hospital Duran i Reynals   (South Korea)

^e Cancer Centers of the Carolinas   (South Korea)

^f Provonix   (South Korea)

^g GLAXOSMITHKLINE   (United Kingdom)

^h ICON Clinical Research   (South Korea)

Author keywords

Breast cancer; Drug interaction; Esomeprazole; Lapatinib; Proton pump inhibitor

Indexed keywords

BACTERIUM ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESOMEPRAZOLE; LAPATINIB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCALCEMIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; RASH; SCREENING TEST; SPINAL CORD COMPRESSION; STEADY STATE; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84885935241     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.45     Document Type: Article

References (23)

1. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355:2733-2743.
2. Sherrill B, Amonkar MM, Sherif B, et al. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010; 15:944-953.
3. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009; 27:5538-5546.
4. Bence AK, Anderson EB, Halepota MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016 m a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs. 2005; 23:39-49.
5. Pehlivanov ND, Olyaee M, Sarosiek I, et al. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther. 2003; 18:883-890.
6. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40mg daily. Aliment Pharmacol Ther. 1998; 12:1235-1240.
7. Hatlebakk JG. Review article: gastric acidity-comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther. 2003; 17:10-15.
8. Norris V, Baisley K, Dunn K, et al. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment Pharmacol Ther. 2007; 25:501-510.
9. Katz PO, Koch KF, Ballard DE, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007; 25:197-205.
10. Andersson T, Rohss K, Bredberg E, et al. Pharmacokinetics and Pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther. 2001; 15:1563-1569.
11. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41:913-958.
12. Klotz U, Scwab M, Treiber G. CYP2C19 polymorphism and proto pump inhibitors. Basic Clin Pharmacol Toxicol. 2004; 95:2-8.
13. Gillen D, Wirz AA, Neithercut WD, et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut. 1999; 44:468-475.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-655.
15. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut. 1995; 36:539-543.
16. Shimatani T, Moriwaki M, Xu J, et al. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis. 2006; 38:802-808.
17. Ford SL, Murray SC, Anderson MT, et al. Overview of drug interactions between brecanavir (BCV) and other concomitant medications. 45th Annual Meeting of IDSA, October 4-7, 2007-San Diego (abstract 446).
18. Hsieh S, Tobien T, Koch KM, Dunn J. Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom. 2004; 18:285-292.
19. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006; 44:297-302.
20. Evans DF, Pye G, Bramley R, et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988; 29:1035-1041.
21. Goldschmiedt M, Feldman M. Age-related changes in gastric acid secretion. Chapter 2. In: Holt PR, Russell, RM, eds. Chronic Gastritis and Hypochlorhydria in the Elderly. Boca Raton, FL: CRC Press; 1993: 13-25.
22. Heikkinen AT, Mönkkönen J. Protein concentration and pH affect the apparent P-glycoprotein-ATPase activation kinetics. Int J Pharmaceut. 2008; 346:169-172.
23. Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009; 27:1191-1196.